Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

achondroplasia News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A new study benchmarks statistical inference and explainable AI to predict craniospinal surgery in pediatric patients with achondroplasia. This research addresses the unique challenges posed by rare diseases, potentially improving surgical decision-making.

Biomarin has secured 18-20% royalties on net sales from Ascendis' achondroplasia drug Yuviwel through a non-exclusive licensing agreement for the active ingredient navepegritide. This deal highlights the financial potential of treatments for achondroplasia.

A new study published in PubMed provides real-world evidence on the effectiveness and safety of vosoritide in Latin American patients with achondroplasia. This research contributes to the understanding of treatment outcomes in diverse populations.

BioMarin's Phase 3 trial of Voxzogo for hypochondroplasia demonstrated efficacy significantly exceeding previous results for achondroplasia. This positive outcome follows earlier safety concerns and positions Voxzogo favorably in the rare skeletal disorder market.

A qualitative study explores the experiences and treatment perspectives of adolescents and young adults with achondroplasia, along with insights from their caregivers. This research highlights the unique challenges faced by this population and informs future treatment approaches.

BioMarin has paused dosing and enrollment in two studies of Voxzogo due to safety concerns, specifically multiple cases of hip injuries reported in other trials. This setback comes as competition intensifies in the achondroplasia market with new entrants like Ascendis Pharma and BridgeBio.

FDA approves Yuviwel for achondroplasia, marking a significant entry into the market and positioning it against BioMarin’s Voxzogo. This approval highlights the competitive landscape as BridgeBio advances its FGFR3 blocker, infigratinib.

BridgeBio's Infigratinib demonstrates exceptional efficacy and safety in the late-stage PROPEL 3 study for achondroplasia, exceeding expectations according to Truist Securities. This promising data positions the drug favorably for future development and potential market entry.

BioMarin is exploring a merger with Amicus Therapeutics to bolster its position against emerging competitors for Voxzogo, its drug for achondroplasia. The deal aims to leverage Amicus's two approved assets to sustain investor confidence amidst market challenges.

Not rare diseases news,news about your rare disease.